Evaluation of Cladribine treatment in refractory celiac disease type II

Table 1 Patient characteristics

Gender (M:F)	18:14
Age of CD diagnosis: median in years (range)	58.5 (38-74)
Age of RCDII diagnosis: median in years (range)	64 (42-78)
Age at the start of 2-CdA treatment: median in years (range)	64 (45-78)
Treatment prior to 2-CdA
None	22
Immunosuppressive drugs	10
Follow-up time: median in months (range)	31 (4-120)
HLA-DQ status
DQ2 heterozygous	17
DQ2 homozygous	12
DQ2 and DQ8	2
Unknown	1
TCR-γ gene rearrangement
Monoclonal	18
Polyclonal	9
Unknown	5
Marsh classification before 2-CdA
Marsh IIIA	13
Marsh IIIB	11
Marsh IIIC	8
Intestinal aberrant IELs before 2-CdA: median in % (range)	61 (21-96)
Body mass index before 2-CdA: median in kg/m2 (range)	21 (16-27)
Albumin level before 2-CdA: median (range, reference value 35-52 g/L)	36 (23-47)
Haemoglobin level before 2-CdA: median in mmol/L (range)	7.8 (6.0-9.8)

2-CdA: 2-chlorodeoxyadenosine; HLA: Human leukocyte antigen; TCR: T-cell receptor.

Table 2 The 1- and 2-yr response rates and the median time to response in the pre-treated (I) and the upfront 2-CdA (II) group

	Treatment(n)		Response (%)		Time to a 50% response rate (mo)
			12 mo	24 mo
Histological response	Group I	10	13	25	36
	Group II	22	20	58	24
	Overall	32	10	47	36 (3-96)
Immunological1 response	Group I	10	11	11	> 60
	Group II	22	52	58	12
	Overall	32	39	41	41 (2-96)
Clinical2 response	Group I	10	67	67	6
	Group II	22	95	95	3
	Overall	32	81	81	3 (2-72)
Overall response	Group I	10	22	38	36
	Group II	22	28	43	30
	Overall	32	25	41	36

¹P = 0.030 and

²P = 0.058 between group I and II.